That’s what the China Food and Drug Administration (CFDA) declared on the blood diagnostic test from Berlin-based Epigenomics‘ proprietary Septin9-Biomarker. Their Septin9 test Epi proColon is filling the need for early detection of colorectal cancer. Data show a huge increase in prevalence in urban China.Just last week we interviewed the CEO of Epigenomics, Thomas Taapken, on the company’s Cancer detection technology and Septin9 test Epi proColon. The colorectal cancer screening test is the first of its kind and has been approved by the EU, CFDA and now by the FDA in the US, too.
Imagine, a simple blood test which can detect one of the deadliest types of cancer.
Indeed over 290 million people in China are estimated to be eligible to colorectal cancer screening, and early detection is the key to saving lives. The Chinese government has even highlighted early CRC screening as a focus in Cancer prevention.
And this type of cancer is on the rise…with one report estimating that the number of colorectal cancer cases between 2012 and 2022 in urban areas of China will double.